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Abstract
The Human Phosphate-Binding protein (HPBP) is a serendipitously discovered lipoprotein that binds phosphate
with high affinity. HPBP belongs to the DING protein family, involved in various biological processes like cell cycle
regulation. We report that HPBP inhibits HIV-1 gene transcription and replication in T cell line, primary peripherical
blood lymphocytes and primary macrophages. We show that HPBP is efficient in naïve and HIV-1 AZT-resistant
strains. Our results revealed HPBP as a new and potent anti HIV molecule that inhibits transcription of the virus,
which has not yet been targeted by HAART and therefore opens new strategies in the treatment of HIV infection.
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Introduction
Human immunodeficiency 1 (HIV-1), identified in 1983
[1], remains a global health threat responsible for a
world-wide pandemic. The introduction of the highly
active antiretroviral therapy (HAART) in 1996 exhibited
the potential of curing acquired immune deficiency syn-
drome (AIDS). Even though an effective AIDS vaccine is
still lacking, HAART has greatly extended survival [2].
AIDS pandemic has stabilized on a global scale in 2008
with an estimated 33 million people infected worldwide
(data from UN, 2008).
However, several problems have been encountered
since the introduction of HAART, and improvements in
the design of drugs for HIV-1 are needed. A drawback of
HAART is that the treatment is very expensive with lim-
itation of its use to western countries. HAART has also
several serious side effects leading to treatment interrup-
tion. Another major concern is related to the emergence
of multidrug resistant viruses which has been reported in
patients receiving HAART [3-5]. Therefore, new antiviral
drugs are needed with activities against both wild type
and mutant viruses. Two major cellular targets for HIV-1
are currently known which have critical role in HIV
pathogenesis, i.e. CD4+ T lymphocytes and monocytes/
macrophages including microglial cells, which are the
central nervous system resident macrophages [6-8]. How-
ever, several drugs being active in CD4+ T lymphocytes
are ineffective in chronically infected macrophages (i.e.
several reverse transcriptase inhibitors) [9], and protease
inhibitors have significantly lower activities in macro-
phages compared to lymphocytes [10]. Finally, many
observations strongly suggest that even long term sup-
pression of HIV-1 replication by HAART cannot totally
eliminate HIV-1. The virus persists in cellular reservoirs
because of viral latency, cryptic ongoing replication or
poor drug penetration [11-13]. Moreover, these cellular
reservoirs are often found in tissue sanctuary sites where
penetration of drugs is restricted, like in the brain
[14-16]. All these considerations (existence of several
reservoirs, tissue-sanctuary sites and multidrug resis-
tance) urge the search for new and original anti HIV-1
treatment strategies. Currently there are seven classes of
antiretroviral (ARV) drugs available in the treatment of
HIV-1-infected patients: nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs), nucleotide reverse tran-
scriptase inhibitors (NtRTIs), non-nucleoside reverse
transcriptase inhibitors (NNRTIs), protease inhibitors
(PIs), entry/fusion inhibitors (EIs), co-receptor inhibitors
(CRIs) and integrase inhibitors (INIs) [17]. The therapy
of HIV-1-infected patients is based on a combination of
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There have been attempts without success to develop
vaccines against HIV- 1 and this field of research needs
new directions [19-21]. Improvement of HAART is
therefore crucial.
We believe that new drugs should target other steps of
the HIV-1 cycle such as transcription since there is no
drug currently available targeting this step. An increasing
number of studies suggest that inhibitors of cellular LTR-
binding factors, such as NF-KB and Sp1 repress LTR-dri-
ven transcription [19,21-24]. Recently, it has been shown
that proteins of the DING family are good candidates to
repress HIV-1 gene transcription [25,26].
More than 40 DING proteins have now been purified,
mostly from eukaryotes [[27] and personal communica-
tion] and most of them are associated with biological pro-
cesses and some diseases [28]. The ubiquitous presence in
eukaryotes of proteins structurally and functionally related
to bacterial virulence factors is intriguing, as is the absence
of eukaryotic genes encoding DING proteins in databases.
However, theoretical arguments together with experimen-
tal evidences supported an eukaryotic origin for DING
proteins [29,30]. A member of the DING family proteins,
HPBP, was serendipitously discovered in human plasma
while performing structural studies on another target, the
HDL-associated human paraoxonase hPON1 [31-33]. The
structure topology is similar to the one described for solu-
ble phosphate carriers of the ABC transporter family
[32-36] that makes HPBP the first potential phosphate
transporter identified in human plasma. Moreover, the
association with hPON1 has been hypothesized to be
involved in inflammation and atherosclerosis processes
[37]. Later, the ab initio sequencing of HPBP by tandem
use of mass spectrometry and X-ray crystallography con-
firmed that its gene was missing from the sequenced
human genome [38]. Immunohistochemistry studies per-
formed in mouse tissues demonstrate that DING proteins
are present in most of tissues, spanning from neurons to
muscle cells and their cellular localization is largely vari-
able, being exclusively nuclear in neurons, or nuclear and
cytoplasmic in muscle cells [30]. Altogether, these localiza-
tions are consistent with the biological function that was
associated to these proteins, especially the regulation/
alteration of cell cycle.
To test whether HPBP is a potential HIV-1 repressor
we carried out experiments in a lymphoblastoid cell line
(Jurkat) and in primary cells (Peripherial Blood Lineage
and macrophage cultures). We report that HPBP represses
HIV-1 replication through the inhibition of its gene tran-
scription. Furthermore, HPBP is also active against mutant
viruses. Evidence that HPBP can block HIV-1 LTR pro-
moted expression and replication should lead to the design
of new drugs which target a not yet targeted step of the
virus cycle i.e. transcription.
Materials and methods
Protein purification
HPBP/HPON1-containing fractions were obtained follow-
ing previously described HPON1 purification protocol
[39]. Then HPBP was purified from these fractions accord-
ing to Renault et al. protocol [33]. HPBP/HPON1-contain-
ing fraction in 25 mM Tris buffer containing 0.1% Triton
X-100, were injected on Bio-Gel HTP hydroxyapatite
(BioRad Laboratories, Munich, Germany) equilibrated
with 10 mM sodium phosphate pH 7.0. This step was fol-
lowed by washing with the same buffer and elution by 400
mM sodium phosphate allowed to separate the two pro-
teins. HPBP was not retained on hydroxyapatite equili-
brated without CaCl2 and was collected in the filtrate. On
the contrary, HPON1 was retained and subsequently
eluted by higher phosphate concentrations.
Cell culture
1G5 cells (a Jurkat stable cell line for LTR-luciferase)
were grown in RPMI 1640 medium supplemented with
10% fetal calf serum and in the presence of penicillin
and streptomycin (100 U/ml). Primary Macrophages
were cultured and prepared as previously described [40].
Antiretroviral compounds
Stock of AZT (Glaxo Wellcome) was prepared as 0.1
mM solution in dimethylsulfoxide (Pierce) and stored at
-70°C. Stock solutions were further diluted in culture
medium immediately prior to use.
Luciferase assays
1G5 cells (a Jurkat stable cell line for LTR-luciferase)
were transfected (5 × 10
6-10
7 cells/transfection) using
DEAE-dextran transfection method with HIV-1 pNL4.3.
Two days later, cells were collected and luciferase activ-
ity was determined using the Dual-GloTM Luciferase
Assay System (Promega). Values correspond to an aver-
age of at least three independent experiments performed
in duplicate.
HIV-1 infection and viral replication
1G5 cells (a Jurkat stable cell line for LTR-luciferase)
were transfected (5 × 10
6-10
7 cells/transfection) using
DEAE-dextran transfection method with HIV-1 pNL4.3.
After 24 h indicated amount of HPBP was added to cell
culture medium. HIV-1 replication was monitored as
described previously [41].
Purified PBLs were prepared from peripheral blood of
healthy donors as described previously [42]. For purified
PBL preparation, Ficoll-Hypaque (Pharmacia, Uppsala,
Sweden)-isolated PBMCs were incubated for 2 h on 2%
gelatincoated plates. Nonadherent cells, 98% that were
PBLs, as assessed by CD45/CD14 detection by flow
cytometry analysis (Simultest Leucogate, Becton
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Ficoll-Hypaque isolation and adherence. PBLs were cul-
tivated in RPMI with 10% (v/v) FBS supplemented with
human recombinant IL-2 (20 IU/ml) following treat-
ment with PHA (5 μg/ml) for 48 h. Cultured in 24-well
plates, cells were electroporated (Biorad Gene Pulser X
Cell) with the complete HIV-1 infectious molecular
clone pNL4.3. For infection experiments, cells were
infected (50 ng/million cells) with a wt lymphotropic
strain pNL4.3 or an AZT resistant lymphotropic strain
(purchased by NIH AIDS research and reference pro-
gram (lot number 0014 A018-G910-6, post AZT iso-
lates) [43]. HIV-1 replication was monitored as
described previously [40].
Macrophages cells were cultured and prepared as pre-
viously described [40]. Cultured in 24-well plates, cells
were transfected using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA, USA) with the complete
HIV-1 infectious molecular clone pNL4.3. For infection
experiments, cells were infected (50 ng/million cells)
with the pseudo typed pNL4.3-VSV 1 virus. Vesicular
stomatitis virus G protein (VSV-G) pseudotyped virions
were produced by cotransfection of 293T cells with 500
ng of VSV-G expressed with plasmid pHCMVg along
with 2 μg of the proviral clone. HIV-1 replication was
monitored as described previously [40]. Values corre-
spond to an average of at least three independent
experiments carried out in duplicates.
MTT assay
Jurkat cells, as well primary cells, i.e PBL and macro-
phages, were seeded in 96-well plates and indicated
amount of HPBP was added to cell culture medium. The
possible cytotoxic effect of the antiretroviral compounds
tested was examined using a 3- [4,5-Dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT) assay [44].
Cells were grown at 37°C/5% CO2 for 6 days in the pre-
sence of antiretroviral compounds at individual concen-
trations of 100, 20, 5, or 0 nM, before removal of the
supernatant and replacement with 0.25 mg/ml MTT
(Sigma) in phenol red-free RPMI-1640 (Life Technolo-
gies). After incubation at 37°C/5% CO2 for 1 h, the
MTT-containing supernatant was removed and the cells
lysed with 5 ml of isopropanol:1M HCl (96:4 v/v). Tripli-
cate 100 _l volumes of dye-containing supernatant were
transferred to a 96-well ELISA-plate (Nunc) and the
absorption measured at 570 nm, using background sub-
traction at 630 nm.
Statistical analysis
Values are the means and SDs of independent experi-
ments. Statistical analysis was performed by Student’s t
test, and differences were considered significant at a
value of p < 0.05.
Results
1. HPBP represses HIV-1 gene transcription and
replication
In order to assess the anti HIV-1 activity of HPBP, we
tested HPBP, HPON1 and the complex HPBP/HPON1,
for their activities on HIV-1 gene transcription and repli-
cation. The complex HPBP-HPON (Figure 1.A and 1.B
lane 2) and the purified HPON1 (Figure 1.A and 1.B lane
4) did not have significant impact neither on HIV-1 repli-
cation nor on HIV-1 gene transcription. However, purified
HPBP strongly repressed HIV-1 replication and transcrip-
tion (respectively 60 and 70% as shown in Figure 1.A and
1.B lane 3). AZT treatment (10 μM), used as a control,
was efficient to repress HIV-1 replication but not HIV-1
gene transcription (Figure 1.A and 1.B lane 5). Heat-inacti-
vated HPBP, used in another control experiment, had no
effect on HIV-1 replication (data not shown).
2. Dose response and cytotoxicity assay for HPBP
Figure 2 shows the dose response effect of HPBP on the
Jurkat cells with an IC50 (50% inhibitory concentration)
equal to 5 nM. To measure the cytotoxic effect of HPBP
on these cells we used the MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] cytotoxicity assay
[44]. Results, shown in Figure 2 (green line), allowed us
to calculate CC50 (50% toxicity concentration) to be
equal to 526 nM. We next performed dose response
experiments and MTT cytotoxicity assays in primary
cells. In Peripherical Blood Cells (PBL), the IC50 is esti-
mated to 5 nM and the CC50 is estimated to 200 nM.
Comparable results were obtained in primary macro-
phages with an IC50 of 5 nM and a CC50 of 140 nM
(see table 1).
3. HPBP is efficient against drug-resistant strain of HIV-1
To assess the anti HIV-1 activity of HPBP against
mutant viruses, we performed a dose response effect of
HPBP on PBL infected with an HIV-1 AZT-resistant
strain (lot number 0014 A018-G910-6, post AZT iso-
lates) [43]. As shown in Figure 3, HPBP is active against
the mutant strain with an IC50 (5 nM) to the same
extent as observed for the wild type strain.
Discussion
HPBP is a member of the DING protein family identi-
fied in eukaryotes for their implication in diverse biolo-
gical processes [28,37]. Here, we show that the human
phosphate binding protein has a potent anti HIV-1
activity. Previous observations suggested that p27
SJ,
another member of the DING protein family isolated
from the plant Hypericum perforatum, represses HIV-1
replication and transcription [25,45,46]. However, it is
noteworthy to precise that this inhibitor effect is dose
dependent. Indeed it was shown by the same group that
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SJ has a dual role on MCP1(monocyte chemoattrac-
tant protein 1) gene transcription being an activator at
low concentration and an inhibitor at high concentra-
tion [47]. This lead us to hypothesize that HPBP might
also have antiviral activities. Since CD4+ T lymphocytes
and cells from monocyte-macrophage lineages are major
targets for HIV-1, we assessed the in vitro antiviral
activity of HPBP in lymphoblastoid cell lines (Jurkat),
primary monocyte/macrophage cells and peripheral
blood lymphocytes presenting laboratory and clinical
isolates of HIV-1. The inhibitory effect of HPBP on
HIV-1 replication is very strong, the IC50 value being in
t h er a n g eo f5n Mt o1 0n M ,a n da l s oc o m p a r e dt o
other canonical drugs currently used in HAART (15 nM
to 6.7 μM for AZT and 40 nM to 8.5 μMf o rt e n o f i v i r )
[48]. At this concentration HPBP is also a potent anti
HIV-1 drug in PBL and in primary macrophages, which
is not true for several other anti HIV-1 drugs. For exam-
ple, 3 RT inhibitors, i.e. Lamivudine, entricitabine and
AZT have different IC50 values when assessed for their
antiviral activity in PBL and macrophages [49]. Further-
more, the CC50 values for HPBP were in the range of
140 nM to 200 nM and the selectivity index CC50/IC50
(ratio between the toxic dose and the inhibitory dose) of
HPBP was in the range of 28 to 40. This high ratio indi-
cates that the therapeutical index should therefore be
high enough for use in in vivo studies.
HPBP also emerged as a promising candidate for drug
development as it targets HIV-1 transcription, a phase
of the HIV-1 cycle not yet targeted by other drugs. In
productive cells, the transcription of the provirus DNA
is regulated by the interplay of a combination of viral
and cellular transcription factors [50-53]. Darbinian and
coll. have identified the protein P27
SJ, which belongs to
the DING protein family and inhibits the activity of the
Figure 1 HPBP represses HIV-1 gene transcription and replication. 1G5 cells were transfected with the pNL4.3 provirus. (1) Mock, (2) HPBP/
HPNO1 (50 nM), (3) HPBP (50 nM), (4) HPON1 (50 nM), and (5) AZT (10 μM) was added 24 h post transfection. Luciferase activity (A) and HIV-1
replication (B) were monitored 48 h post transfection. Values correspond to an average of at least three independent experiments carried out in
duplicate. The purity and the size of purified-HPBP were controlled by SDS-PAGE and coomassie blue staining (C).
Figure 2 Dose response and cytotoxicity test. 1G5 cells were
infected with NL4-3 and treated with increasing amount of HPBP
24 h post transfection. Luciferase activity was assessed 48 h post
transfection. MTT test were performed in the same conditions than
the dose response experiment. HIV-1 inhibition (grey columns) and
percentage of living cell (green line) are shown relative to the mock
treated conditions as 100%. Values correspond to an average of at
least three independent experiments performed in duplicate.
Table 1 CC50 and IC50 values in peripheral blood
lymphocytes and in primary macrophages
Peripheral Blood Lymphocytes Primary Macrophages
CC50 200 nM 140 nM
IC50 5 nM 5 nM
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and Tat [45,46]. Targeting cellular factors, i.e. NF-IL6
has the advantage that resistance to these new drugs
should evolve with a lower probability. More impor-
tantly, interfering with Tat will ensure a strong and
selective repression of HIV-1 replication.
Since its introduction in 1996, antiretroviral therapy
has changed the clinical course of HIV and AIDS. How-
ever drug resistance has occurred with all of the antire-
troviral agents. It is now a major public health concern
and it is crucial to design new antiretroviral drugs
[54,55]. These new drugs should inhibit HIV replication
by targeting new steps within the viral life cycle. Of great
interest HPBP, which targets transcription, is as effective
against drug resistant HIV strains as to wild type strains,
highlighting the potential therapeutic advantage of
HPBP. The molecular mechanism of action is unknown
but currently under investigation. In the future, pharma-
cophores (“part of a molecule that is necessary to ensure
the optimal interactions with a specific biological target
and to trigger (or block) its biological response”)c a nb e
inferred from the characterization of these biochemical
studies.
In conclusion, this work indicates that HPBP has a
potent anti HIV activity through the inhibition of tran-
scription a not yet targeted phase of the virus cycle.
However additional experiments regarding the HPBP
impact on HIV replication and gene transcription have
to be performed on other viral strains including several
other mutant strains (NRTIs, NNRTIs and protease
inhibitors). We believe that this protein or its derivatives
are potentially interesting molecules and deserve further
studies. As suggested for X-DING-CD4 [26], this work
could also uncover a new function for proteins belong-
ing to the DING protein family, that is a role in the
innate response to infection including HIV-1. New
investigations will be needed in order to precise the
importance of the DING proteins. It has been previously
shown that HPBP is tightly associated with HPON1 [56].
The search of a correlation between the HPBP abun-
dance, its biologic availability, the HPBP/HPON ratio
and the non progression in the disease AIDS in the
“elite non progressors cohort” will be of great interest.
Finally DING proteins may constitute a marker for
AIDS progression since it has been shown that both
HPON activity and its concentration have been altered
in the presence of HIV-1 [57,58].
Acknowledgements
This work was supported by grants from the Agence Nationale de
Recherche sur le SIDA (ANRS), Sidaction and Institut Universitaire de France
to OR and from CNRS to TC. ME is a fellow supported by the IEF Marie Curie
program (grant No. 252836). TC is a fellow supported by the Belgian Fund
for Scientific Research (FRS-FNRS, Belgium). Andrea J is a fellow supported
by the “Région Alsace”. VLD is supported by a doctoral grant from the
French Ministry of Research.
Author details
1Institut de Parasitologie et Pathologie Tropicale, EA 4438, Université de
Strasbourg, 3 rue Koeberlé, 67000 Strasbourg, France.
2Laboratoire URMITE -
UMR 6236 Faculté de Médecine, 27, Bvd Jean Moulin, 13385 Marseille Cedex
5 France.
3Unité d’enzymologie, Département de Toxicologie, centre de
recherche du service de santé des armées, 38702 la Tronche, France.
4IUT
Louis Pasteur de Schiltigheim, 1 Allée d’Athènes, 67300 Schiltigheim, France.
5Institut Universitaire de France, 103 Bvd St-Michel, 75005 Paris, France.
6Cellular and Molecular Biology Unit, FUSAGx, Gembloux, Belgium.
7Weizmann Institute of Science, Biological Chemistry, Rehovot, Israel.
Authors’ contributions
TC, ME, Alicia J, carried out dose response and cytotoxicity assays in
lymphocytes and macrophages. Andrea J participated in dose response and
cytotoxicity assays in macrophages. VLD and HH carried experiments with
heat-inactivated HPBP. CS carried out experiments in Jurkat cell line. GG and
PM purified HPBP. Ermanno C and OR participated in the design of the
study. Eric C and CS conceived of the study, participated in its design and
coordination and wrote the paper. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 April 2011 Accepted: 15 July 2011 Published: 15 July 2011
References
1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J,
Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, et al: Isolation of a
T-lymphotropic retrovirus from a patient at risk for acquired immune
deficiency syndrome (AIDS). Science 1983, 220:868-871.
2. Geeraert L, Kraus G, Pomerantz RJ: Hide-and-seek: the challenge of viral
persistence in HIV-1 infection. Annu Rev Med 2008, 59:487-501.
3. Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D’Aquila RT,
Quinn TC, Siliciano JD, Siliciano RF, Persaud D: HIV-1 drug resistance
Figure 3 Dose response of HPBP on an AZT-resistant HIV-1
strain. PBL were infected with AZT resistant strain of HIV-1.
Different concentrations of HPBP were added 24 h post infection
and the HIV-1 replication was monitored 3 days post infection by
quantification of the viral p24 protein. HIV-1 inhibition (grey
columns) and percentage of living cell (green line) are shown
relative to the mock treated conditions as 100%. The 100% level of
replication correspond to an average 1.1 ng of p24 protein/ml.
Values correspond to an average of at least three independent
experiments performed in duplicate.
Cherrier et al. Virology Journal 2011, 8:352
http://www.virologyj.com/content/8/1/352
Page 5 of 7profiles in children and adults with viral load of <50 copies/ml receiving
combination therapy. Jama 2001, 286:196-207.
4. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, Ray SC,
Persaud D, Siliciano RF: Genotypic analysis of HIV-1 drug resistance at the
limit of detection: virus production without evolution in treated adults
with undetectable HIV loads. J Infect Dis 2004, 189:1452-1465.
5. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr,
Gallant JE, Quinn TC, Jackson B, et al: Intermittent HIV-1 viremia (Blips)
and drug resistance in patients receiving HAART. Jama 2005,
293:817-829.
6. Le Douce V, Herbein G, Rohr O, Schwartz C: Molecular mechanisms of
HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology
2010, 7:32.
7. Redel L, Le Douce V, Cherrier T, Marban C, Janossy A, Aunis D, Van Lint C,
Rohr O, Schwartz C: HIV-1 regulation of latency in the monocyte-
macrophage lineage and in CD4+ T lymphocytes. J Leukoc Biol 2009.
8. Herbein G, Varin A: The macrophage in HIV-1 infection: from activation
to deactivation? Retrovirology 2010, 7:33.
9. Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF:
Macrophages and HIV infection: therapeutical approaches toward this
strategic virus reservoir. Antiviral Res 2002, 55:209-225.
10. Perno CF, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, Calio R,
Yarchoan R: Relative potency of protease inhibitors in monocytes/
macrophages acutely and chronically infected with human
immunodeficiency virus. J Infect Dis 1998, 178:413-422.
11. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H,
Hermankova M, Chadwick K, Margolick J, Quinn TC, et al: Quantification of
latent tissue reservoirs and total body viral load in HIV-1 infection.
Nature 1997, 387:183-188.
12. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE,
Quinn TC, Chadwick K, Margolick J, Brookmeyer R, et al: Identification of a
reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Science 1997, 278:1295-1300.
13. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A,
Racz P, Perelson AS, Korber BT, et al: Quantifying residual HIV-1 replication
in patients receiving combination antiretroviral therapy. N Engl J Med
1999, 340:1605-1613.
14. McGee B, Smith N, Aweeka F: HIV pharmacology: barriers to the
eradication of HIV from the CNS. HIV Clin Trials 2006, 7:142-153.
15. Sawchuk RJ, Yang Z: Investigation of distribution, transport and uptake of
anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev 1999,
39:5-31.
16. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B:
Discrepancies between protease inhibitor concentrations and viral load
in reservoirs and sanctuary sites in human immunodeficiency virus-
infected patients. Antimicrob Agents Chemother 2003, 47:238-243.
17. De Clercq E: Antiretroviral drugs. Curr Opin Pharmacol 2010, 10:507-515.
18. Taiwo B, Murphy RL, Katlama C: Novel antiretroviral combinations in
treatmentexperienced patients with HIV infection: rationale and results.
Drugs 70:1629-1642.
19. Baba M: Recent status of HIV-1 gene expression inhibitors. Antiviral Res
2006, 71:301-306.
20. Gatignol A: Transcription of HIV: Tat and cellular chromatin. Adv
Pharmacol 2007, 55:137-159.
21. Stevens M, De Clercq E, Balzarini J: The regulation of HIV-1 transcription:
molecular targets for chemotherapeutic intervention. Med Res Rev 2006,
26:595-625.
22. Baba M: Cellular factors as alternative targets for inhibition of HIV-1.
Antiviral Res 1997, 33:141-152.
23. De Clercq E: New anti-HIV agents and targets. Med Res Rev 2002, 22:531-565.
24. Daelemans D, Vandamme AM, De Clercq E: Human immunodeficiency
virus gene regulation as a target for antiviral chemotherapy. Antivir
Chem Chemother 1999, 10:1-14.
25. Darbinian-Sarkissian N, Darbinyan A, Otte J, Radhakrishnan S, Sawaya BE,
Arzumanyan A, Chipitsyna G, Popov Y, Rappaport J, Amini S, Khalili K: p27
(SJ), a novel protein in St John’s Wort, that suppresses expression of
HIV-1 genome. Gene Ther 2006, 13:288-295.
26. Lesner A, Shilpi R, Ivanova A, Gawinowicz MA, Lesniak J, Nikolov D,
Simm M: Identification of X-DING-CD4, a new member of human DING
protein family that is secreted by HIV-1 resistant CD4(+) T cells and has
anti-viral activity. Biochem Biophys Res Commun 2009, 389:284-289.
27. Berna A, Bernier F, Chabriere E, Elias M, Scott K, Suh A: For whom the bell
tolls? DING proteins in health and disease. Cell Mol Life Sci 2009,
66:2205-2218.
28. Elias M, Liebschner D, Gotthard G, Chabriere E: Structural insights and ab
initio sequencing within the DING proteins family. J Synchrotron Radiat
2011, 18:45-49.
29. Berna A, Bernier F, Chabriere E, Perera T, Scott K: DING proteins; novel
members of a prokaryotic phosphate-binding protein superfamily which
extends into the eukaryotic kingdom. Int J Biochem Cell Biol 2008, 40:170-175.
30. Collombet JM, Elias M, Gotthard G, Four E, Renault F, Joffre A, Baubichon D,
Rochu D, Chabriere E: Eukaryotic DING proteins are endogenous: an
immunohistological study in mouse tissues. PLoS One 2010, 5:e9099.
31. Contreras-Martel C, Carpentier P, Morales R, Renault F, Chesne-Seck ML,
Rochu D, Masson P, Fontecilla-Camps JC, Chabriere E: Crystallization and
preliminary X-ray diffraction analysis of human phosphate-binding
protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006, 62:67-69.
32. Morales R, Berna A, Carpentier P, Contreras-Martel C, Renault F,
Nicodeme M, Chesne-Seck ML, Bernier F, Dupuy J, Schaeffer C, et al:
Serendipitous discovery and X-ray structure of a human phosphate
binding apolipoprotein. Structure 2006, 14:601-609.
33. Renault F, Chabriere E, Andrieu JP, Dublet B, Masson P, Rochu D: Tandem
purification of two HDL-associated partner proteins in human plasma,
paraoxonase (PON1) and phosphate binding protein (HPBP) using
hydroxyapatite chromatography. J Chromatogr B Analyt Technol Biomed
Life Sci 2006, 836:15-21.
34. Fokine A, Morales R, Contreras-Martel C, Carpentier P, Renault F, Rochu D,
Chabriere E: Direct phasing at low resolution of a protein copurified with
human paraoxonase (PON1). Acta Crystallogr D Biol Crystallogr 2003,
59:2083-2087.
35. Liebschner D, Elias M, Moniot S, Fournier B, Scott K, Jelsch C, Guillot B,
Lecomte C, Chabriere E: Elucidation of the phosphate binding mode of
DING proteins revealed by subangstrom Xray crystallography. JA m
Chem Soc 2009, 131:7879-7886.
36. Morales R, Berna A, Carpentier P, Contreras-Martel C, Renault F,
Nicodeme M, Chesne-Seck ML, Bernier F, Dupuy J, Schaeffer C, et al:
[Discovery and crystallographic structure of human apolipoprotein]. Ann
Pharm Fr 2007, 65:98-107.
37. Webb MR: A tale of the unexpected. Structure 2006, 14:391-392.
38. Diemer H, Elias M, Renault F, Rochu D, Contreras-Martel C, Schaeffer C, Van
Dorsselaer A, Chabriere E: Tandem use of X-ray crystallography and mass
spectrometry to obtain ab initio the complete and exact amino acids
sequence of HPBP, a human 38-kDa apolipoprotein. Proteins 2008,
71:1708-1720.
39. Gan ZR, Lewis SD, Stone JR, Shafer JA: Reconstitution of catalytically
competent human zeta-thrombin by combination of zeta-thrombin
residues A1-36 and B1-148 and an Escherichia coli expressed
polypeptide corresponding to zeta-thrombin residues B149-259.
Biochemistry 1991, 30:11694-11699.
40. Leone C, Le Pavec G, Meme W, Porcheray F, Samah B, Dormont D, Gras G:
Characterization of human monocyte-derived microglia-like cells. Glia
2006, 54:183-192.
41. Rohr O, Lecestre D, Chasserot-Golaz S, Marban C, Avram D, Aunis D, Leid M,
Schaeffer E: Recruitment of Tat to heterochromatin protein HP1 via
interaction with CTIP2 inhibits human immunodeficiency virus type 1
replication in microglial cells. J Virol 2003, 77:5415-5427.
42. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J,
O’Brien WA, Verdin E: Apoptosis of CD8+ T cells is mediated by
macrophages through interaction of HIV gp120 with chemokine
receptor CXCR4. Nature 1998, 395:189-194.
43. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to
zidovudine (AZT) isolated during prolonged therapy. Science 1989,
243:1731-1734.
44. Mosmann T: Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Methods
1983, 65:55-63.
45. Darbinian N, Czernik M, Darbinyan A, Elias M, Chabriere E, Bonasu S,
Khalili K, Amini S: Evidence for phosphatase activity of p27SJ and its
impact on the cell cycle. J Cell Biochem 2009, 107:400-407.
46. Darbinian N, Gomberg R, Mullen L, Garcia S, White MK, Khalili K, Amini S:
Suppression of HIV-1 transcriptional elongation by a DING phosphatase.
J Cell Biochem 2011, 112:225-232.
Cherrier et al. Virology Journal 2011, 8:352
http://www.virologyj.com/content/8/1/352
Page 6 of 747. Mukerjee R, Deshmane SL, Darbinian N, Czernik M, Khalili K, Amini S,
Sawaya BE: St. John’s Wort protein, p27SJ, regulates the MCP-1
promoter. Mol Immunol 2008, 45:4028-4035.
48. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ: Tenofovir exhibits low
cytotoxicity in various human cell types: comparison with other
nucleoside reverse transcriptase inhibitors. Antiviral Res 2002, 54:37-45.
49. Hazen R, Lanier ER: Relative anti-HIV-1 efficacy of lamivudine and
emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic
Syndr 2003, 32:255-258.
50. Garcia JA, Harrich D, Soultanakis E, Wu F, Mitsuyasu R, Gaynor RB: Human
immunodeficiency virus type 1 LTR TATA and TAR region sequences
required for transcriptional regulation. Embo J 1989, 8:765-778.
51. Kingsman SM, Kingsman AJ: The regulation of human immunodeficiency
virus type-1 gene expression. Eur J Biochem 1996, 240:491-507.
52. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ: A compilation of
cellular transcription factor interactions with the HIV-1 LTR promoter.
Nucleic Acids Res 2000, 28:663-668.
53. Rohr O, Marban C, Aunis D, Schaeffer E: Regulation of HIV-1 gene
transcription: from lymphocytes to microglial cells. J Leukoc Biol 2003,
74:736-749.
54. Deeks SG: Treatment of antiretroviral-drug-resistant HIV-1 infection.
Lancet 2003, 362:2002-2011.
55. Kozal MJ: Drug-resistant human immunodefiency virus. Clin Microbiol
Infect 2009, 15(Suppl 1):69-73.
56. Rochu D, Chabriere E, Renault F, Elias M, Clery-Barraud C, Masson P:
Stabilization of the active form(s) of human paraoxonase by human
phosphate-binding protein. Biochem Soc Trans 2007, 35:1616-1620.
57. Parra S, Alonso-Villaverde C, Coll B, Ferre N, Marsillach J, Aragones G,
Mackness M, Mackness B, Masana L, Joven J, Camps J: Serum paraoxonase-
1 activity and concentration are influenced by human
immunodeficiency virus infection. Atherosclerosis 2007, 194:175-181.
58. Parra S, Marsillach J, Aragones G, Beltran R, Montero M, Coll B, Mackness B,
Mackness M, Alonso-Villaverde C, Joven J, Camps J: Paraoxonase-1 gene
haplotypes are associated with metabolic disturbances, atherosclerosis,
and immunologic outcome in HIV-infected patients. J Infect Dis 2010,
201:627-634.
doi:10.1186/1743-422X-8-352
Cite this article as: Cherrier et al.: Human-Phosphate-Binding-Protein
inhibits HIV-1 gene transcription and replication. Virology Journal 2011
8:352.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cherrier et al. Virology Journal 2011, 8:352
http://www.virologyj.com/content/8/1/352
Page 7 of 7